A Phase 2 trial of MC2-32 (RGRN-305) in Pyoderma Gangrenosum
Latest Information Update: 16 May 2024
At a glance
- Drugs RGRN-305 (Primary)
- Indications Pyoderma gangrenosum
- Focus Adverse reactions
Most Recent Events
- 16 May 2024 New trial record
Latest Information Update: 16 May 2024